Radiotracer properties determined by high performance liquid chromatography: A potential tool for brain radiotracer discovery

Nuclear Medicine and Biology

Volumn 39, Issue 1, 2012, Pages 127-135

  Tavares, Adriana Alexandre S ^a   Lewsey, James ^a   Dewar, Deborah ^a   Pimlott, Sally L ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Brain uptake; HPLC; Lipophilicity; Non specific binding; Radiotracer discovery; SPECT and PET

Indexed keywords

(N METHYL) 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; 1 (2 IODOPHENYL) N METHYL N (1 METHYLPROPYL) 3 ISOQUINOLINECARBOXAMIDE; 2 [[2 [(DIMETHYLAMINO)METHYL]PHENYL]THIO] 5 IODOPHENYLAMINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 AMINO 4 (2 DIMETHYLAMINO METHYLPHENYLSULFANYL)BENZONITRILE; 3 IODO 6 METHOXYBENZAMIDE; 3 QUINUCLIDINYL 4 IODOBENZILATE; 5 IA 85380; I PK 11195; IOMAZENIL; IOMETOPANE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN; DRUG BINDING; DRUG PENETRATION; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PARTITION COEFFICIENT; PLASMA PROTEIN BINDING; RADIOACTIVITY;

BLOOD PROTEINS; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84855316343     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.06.011     Document Type: Article

References (58)

1. Guo Q., Brady M., Gunn R. A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development. J Nucl Med 2009, 50:1715-1723.
2. Laruelle M., Slifstein M., Huang Y. Relationships between Radiotracer Properties and Image Quality in Molecular Imaging of the Brain with Position Emission Tomography. Mol Imag Biol 2003, 5:363-375.
3. Wong D., Pomper M. Predicting the Success of a Radiopharmaceutical for In Vivo Imaging of Central Nervous System Neuroreceptor Systems. Mol Imag Biol 2003, 5:350-362.
4. Waterhouse R.N. Determination of Lipophilicity and Its Use as a Predictor of Blood-Brain Barrier Penetration of Molecular Imaging Agents. Mol Imag Biol 2003, 5:376-389.
5. Yang C., Cai S., Lui H., Pidgeon C. Immobilized Artificial Membranes - screens for drug membrane interaction. Adv Drug Deliv Rev 1996, 23:229-256.
6. Ong S., Lui H., Pidgeon C. Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 1996, 728:113-128.
7. Valko K., Nunhuck S., Bevan C., Abraham M., Reynolds D. Fast Gradient HPLC Method to Determine Compounds Binding to Human Serum Albumin. Relationships with Octanol/Water and Immobilized Artificial Membrane Lipophilicity. J Pharm Sci 2003, 92:2236-2248.
8. Clark D. In silico prediction of blood-brain barrier permeation. Drug Discovery Today 2003, 8:927-933.
9. Innis R., Cunningham V., Delforge J., Fujita M., Gjedde A., Gunn R., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27:1533-1539.
10. 123I]ADAM in healthy human subjects: preliminary results. Eur J Nucl Med 2003, 30:132-136.
11. 123I] ADAM tracer. Comput Methods Programs Biomed 2008, 92:294-298.
12. Abi-Dargham A., Innis R.B., Wisniewski G., Baldwin R.M., Neumeyer J.L., Seibyl J.P. Human biodistribution and dosimetry of iodine-123-fluoroalkyl analogs of β-CIT. Eur J Nucl Med 1997, 24:1422-1425.
13. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994, 14:982-994.
14. 11C-DASB Determined from Human Whole-Body PET. J Nucl Med 2004, 45:1555-1559.
15. 11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies. J Cereb Blood Flow Metab 2001, 21:1342-1353.
16. 18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imag 2003, 30:519-524.
17. Kung H., Alavi A., Chang W., Kung M.-P., Keyes J.W., Velchik M.G., et al. In Vivo SPECT Imaging of CNS D-2 Dopamine Receptors: Initial Studies with Iodine-123-IBZM in Humans. J Nucl Med 1990, 31:573-579.
18. 123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: A critical evaluation of the single-scan approach. Neuroimage 2008, 42:548-558.
19. Dey H.M., Seibyl J.P., Stubbs J.B., Zoghbi S.S., Baldwin R.M., Smith E.O., et al. Human Biodistribution and Dosimetry of the SPECT Benzodiazepine Receptor Radioligand Iodine-123-lomazenil. J Nucl Med 1994, 35:399-404.
20. Abi-Dargham A., Laruelle M., Seibyl J., Rattner Z., BaldWin R.M., Zoghbi S.S., et al. SPECT Measurement of Benzodiazepine Receptors in Human Brain with Iodine-123-Iomazenil: Kinetic and Equilibrium Paradigms. J Nucl Med 1994, 35:228-238.
21. 123I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor. Eur J Nucl Med 2000, 27:1326-1333.
22. 18F-FDDNP PET. J Nucl Med 2009, 50:191-197.
23. 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imag 2010, 37:606-612.
24. 11C]PK11195 brain studies. J Cereb Blood Flow Metab 2005, 25:842-851.
25. Saha G.B., Maclntyre W.J., Go R.T. Radiopharmaceuticals for Brain Imaging. Semin Nucl Med 1994, 24:324-349.
26. 123I]-I-QNB: Methodological considerations. Nucl Med Biol 2004, 31:583-590.
27. 123I]5-I-A-85380 in healthy human subjects. Eur J Nucl Med 2002, 29:183-190.
28. 123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 2004, 18:337-344.
29. 123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imag 2003, 30:1620-1629.
30. Valko K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J Chromatogr A 2004, 1037:299-310.
31. Valko K., Bevan C., Reynolds D. Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to logP/logD. Anal Chem 1997, 69:2022-2029.
32. Pidgeon C., Ong S., Lui H., Qiu X., Pidgeon M., Dantzig A., et al. IAM Chromatography: An in Vitro Screen for Predicting Drug Membrane Permeability. J Med Chem 1995, 38:590-594.
33. Giaginis C., Tsantili-Kakoulidou A. Alternative Measures of Lipophilicity: From Octanol-Water Partitioning to IAM Retention. J Pharm Sci 2008, 97:2984-3004.
34. Giaginis C., Tsantili-Kakoulidou A. Current State of Art in HPLC Methodology for Lipophilicity Assessment of Basic Drugs: A Review. J Liq Chromatogr Related Technol 2008, 31:79-96.
35. Taillardat-Bertschinger A., Galland A., Carrupt P.-A., Testa B. Immobilized artificial membrane liquid chromatography: proposed guidelines for technical optimization of retention measurements. J Chromatogr A 2002, 953:39-53.
36. Valko K. HPLC-Based Measurements of Various Lipophilicity Parameters to Aid Drug Design. LCGC North America 2007, 25:284-291.
37. Oya S., Choi S.-R., Hou C., Mu M., Kung M.-P., Acton P.D., et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): An Improved Serotonin Transporter Ligand. Nucl Med Biol 2000, 27:249-254.
38. Kawai K., Fujibayashi Y., Saji H., Yonekura Y., Konishi J., Kubodera A., et al. A Strategy for the Study of CerebralAmino Acid Transport Using Iodine-123-Labeled Amino Acid Radiopharmaceutical: 3-Iodo-alpha-methyl-Ltyrosine. J Nucl Med 1991, 32:819-824.
39. 11C]AFM. J Cereb Blood Flow Metab 2002, 22:1377-1398.
40. 18F]fluoroethyl)-L-Tyrosine for Tumor Imaging. J Nucl Med 1999, 40:205-212.
41. 123I]IBZM in rat brain. Nucl Med Biol 2001, 28:383-389.
42. Beer H.-F., Bläuenstein P.A., Hasler P.H., Delaloye B., Riccabona G., Bangerl I., et al. In Vitro and In Vivo Evaluation of Iodine-123-Ro 16-0154: A New Imaging Agent for SPECT Investigations of Benzodiazepine Receptors. J Nucl Med 1990, 31:1007-1014.
43. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., et al. 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6-(2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients. J Nucl Med 2007, 48:553-561.
44. 11C](R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with positron emission tomography. Eur J Nucl Med Mol Imag 2009, 36:671-682.
45. Blasberg R., Patlak C., Hiraga S., Pettigrew K., Francis B., Gibson R., et al. Kinetic Analysis of IQNB and the Muscarinic ACh-Receptor Systemin Brain. J Nucl Med 1985, 26:827.
46. Saji H., Ogawa M., Ueda M., Ilda Y., Magata Y., Tominaga A., et al. Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 2002, 16:189-200.
47. Ohtsuki S., Terasaki T. Contribution of Carrier-Mediated Transport System to the Blood-Brain Barrier as a Supporting and Protective Interface for the Brain; Importance for CNS Drug Discovery and Development. Pharm Res 2007, 24:1745-1758.
48. Pardridge W. CNS Drug Design Based on Principles of Blood-Brain Barrier Transport. J Neurochem 1998, 70:1781-1792.
49. Singh S., Mehta J. Measurement of drug-protein binding by immobilized human serum albumin-HPLC and comparation with ultrafiltration. J Chromatogr B 2006, 834:108-116.
50. Eckelman W.C., Kilbourn M.R., Mathis C.A. Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!. Nucl Med Biol 2009, 36:235-237.
51. Eckelman W.C., Mathis C.A. Discussion of targeting proteins in vivo: in vitro guidelines. Nucl Med Biol 2006, 33:161-164.
52. Scherrmann J.-M. Drug delivery to brain via the blood-brain barrier. Vascul Pharmacol 2002, 38:349-354.
53. Alavijeh M., Chishty M., Qaiser M., Palmer A. Drug Metabolism and Pharmacokinetics, the Blood-Brain Barrier, and Central Nervous System Drug Discovery. NeuroRx 2005, 2:554-571.
54. Abbott N. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discovery Today: Technologies 2004, 1:407-416.
55. Jeffrey P., Summerfield S. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 2007, 37:1135-1151.
56. Liu X., Chen C., Smith B. Progress in Brain Penetratuion Evaluation in Drug Discovery and Development. J Pharmacol Exp Ther 2008, 325:349-356.
57. Pike V. PET radiotracers: crossing the bloo-brain barrier and surviving the metabolism. Trends Pharmacol Sci 2009, 30:431-440.
58. Pardridge W. The Blood-Brain Barrier: Bottleneck in Brain Drug Development. NeuroRx 2005, 2:3-14.